Laboratoires Cyclopharma SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Laboratoires Cyclopharma SA - overview
Established
2000
Location
-, -, France
Primary Industry
Medical Devices & Equipment
About
Laboratoires Cyclopharma SA is a French company specializing in the development and commercialization of innovative radiopharmaceuticals for medical imaging and therapy, focusing on enhancing diagnostic accuracy in oncology. Founded in 2000, Laboratoires Cyclopharma SA operates in France and focuses on developing radiopharmaceuticals for medical applications. The company was acquired by Denos from previous investors including Sofimac Partners and Tikehau Capital. The company has successfully raised EUR 4.
615 mn in its latest funding round led by IXO Private Equity, bringing the total amount raised to EUR 4. 615 mn with a current valuation of EUR 28. 342 mn. Laboratoires Cyclopharma specializes in the development and commercialization of innovative radiopharmaceuticals primarily designed for medical imaging and therapy.
Its core offerings include diagnostic and therapeutic agents that enhance imaging accuracy, particularly for oncology. The company's products are marketed to hospitals and imaging centers across Europe and Asia, addressing the growing demand for advanced imaging solutions. In 2023, Laboratoires Cyclopharma reported a revenue of EUR 91. 69 mn and an EBITDA of EUR 18.
76 mn. Revenue is generated through direct sales of its radiopharmaceutical products to healthcare institutions, supporting B2B relationships with hospitals and imaging centers. Laboratoires Cyclopharma plans to leverage recent funding to expand its product offerings and enter new markets. Future initiatives include launching new radiopharmaceutical products aimed at enhancing diagnostic capabilities by the end of 2024.
The company is also targeting expansion into emerging healthcare markets in Asia and the Middle East within the next three years.
Current Investors
Sofimac Partners, Omnes Capital, Tikehau Investment Management
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment, Monitoring Equipment
Website
www.cyclopharma.fr
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Laboratoires Cyclopharma SA - timeline of key events
Laboratoires Cyclopharma SA - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 21,969,794 | 23,867,512 | 26,235,296 | 31,841,257 | 55,470,765 | 68,491,390 | - | - | - |
| % Revenue Growth (YoY) | - | 8.6% | 9.9% | 21.4% | 74.2% | 23.5% | - | - | - |
| EBITDA (USD) | 2,911,079 | 2,186,459 | 2,512,683 | 5,216,339 | 7,342,333 | 12,706,473 | - | - | - |
| Operating Income (USD) | 750,849 | 39,056 | 298,870 | 2,767,701 | 4,922,692 | 10,236,182 | - | - | - |
| Operating Margin | 3.4% | 0.2% | 1.1% | 8.7% | 8.9% | 14.9% | - | - | - |
| % EBITDA Margin | 13.3% | 9.2% | 9.6% | 16.4% | 13.2% | 18.6% | - | - | - |
| NET Income (USD) | 536,174 | 477,906 | 515,533 | 1,279,951 | 3,571,444 | 8,092,614 | - | - | - |
| % Net Margin | 2.4% | 2.0% | 2.0% | 4.0% | 6.4% | 11.8% | - | - | - |
Laboratoires Cyclopharma SA - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Cyclopharma's French Commercial and Manufacturing Operations | - |
Displaying 1 - 1 of 1
Laboratoires Cyclopharma SA - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.